Adrián Alegre Amor-rekin lankidetzan egindako argitalpenak (12)

2024

  1. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

2013

  1. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma: Results from a GEM/PETHEMA study

    British Journal of Haematology, Vol. 163, Núm. 5, pp. 581-589

2012

  1. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

    Haematologica, Vol. 97, Núm. 4, pp. 616-621

2010

  1. Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología

    Medicina Clinica, Vol. 134, Núm. 6, pp. 268-278

2008

  1. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression

    Haematologica, Vol. 93, Núm. 4, pp. 560-565

  2. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: The prognostic impact of achieving molecular response

    British Journal of Haematology, Vol. 142, Núm. 5, pp. 766-774

2006

  1. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study

    Blood, Vol. 108, Núm. 7, pp. 2165-2172

  2. Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma

    Hematological Oncology, Vol. 24, Núm. 4, pp. 205-211

2005

  1. Eritropoyetina en Hematología

    Editorial Médica Panamericana S.A.

2004

  1. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

    Leukemia, Vol. 18, Núm. 4, pp. 856-863

2000

  1. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

    Hematology Journal, Vol. 1, Núm. 1, pp. 28-36